Skip to main content
. 2018 Jan 29;67(5):1754–1767. doi: 10.1002/hep.29477

Figure 3.

Figure 3

Subgroup analyses for the key secondary endpoint of improvement in fibrosis by ≥1 stage and no worsening of SH (mITT population). Response by baseline NAS stratification, fibrosis stage (NASH CRN system), hepatocellular ballooning grade, lobular inflammation, steatosis, sex, age, BMI, T2DM, PNPLA3 genotype, and region. aOR and 95% CI not calculable. Abbreviations: mITT, modified intent‐to‐treat; PNPLA3, patain‐like phospholipase domain‐containing protein 3.